Stockreport

Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ™ (sodium oxybate) Extended-Release Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients...

Avadel Pharmaceuticals plc - Ordinary Share  (AVDL) 
Last avadel pharmaceuticals plc - ordinary share earnings: 3/12 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: avadel.com
PDF -- LUMRYZ is the only FDA-approved once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcol [Read more]